Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dexamethasone + ibuprofen is a combination treatment regimen being investigated by WellSpan Health for the management of acute osteoarthritis pain in patients presenting to the emergency department. Dexamethasone is a potent synthetic glucocorticoid that acts as an anti-inflammatory agent by binding to the glucocorticoid receptor, thereby inhibiting the expression of pro-inflammatory genes and potentially exerting chondroprotective effects. Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase enzymes (COX-1 and COX-2) to reduce prostaglandin synthesis. This specific regimen, evaluated in the NCT06603662 clinical trial, involves a single 10 mg oral dose of dexamethasone administered alongside a 5-day course of ibuprofen to assess whether the addition of a systemic steroid provides superior analgesic relief compared to NSAID monotherapy for acute flares of osteoarthritis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on dexamethasone + ibuprofen.